Alert detail
LCD L38816: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
What changed
Billing changes for cancer testing impact providers significantly.
Who’s affected: Oncology billing teams · Effective: January 2, 2022
Affected codes
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 24 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.